Why the study?
Does reserpine offer advantages over other step-two antihypertensive drugs in elderly hypertensive patients regarding cost, side-effects, and dosing convenience?
Does reserpine offer advantages over other step-two antihypertensive drugs in elderly hypertensive patients regarding cost, side-effects, and dosing convenience?
This review advocates for reconsidering reserpine as a viable step-two antihypertensive option for elderly patients based on practical and economic factors.
May support reserpine reconsideration in elderly hypertension for cost and convenience; hypothesis-generating without randomized confirmation.
Antihypertensives are among the most commonly prescribed drugs for the elderly. Several studies have discussed the benefits of stepped-care drug therapy for hypertension in the elderly, and propranolol, methyldopa, and more recently, clonidine and prazosin have been recommended as step-two antihypertensive drugs. Recent articles omit reserpine as an alternative. A case is made for the use of reserpine by comparing factors of special importance to most elderly: cost, side-effects, frequency of dosage, number of tablets, and the effect of omitted doses.
No takes yet. Share an insight, caveat, or question.
Luxenberg et al. (1983) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: